Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
HoLEP improves outcomes in patients with LUTS related to benign prostatic enlargement
May 15th 2022“HoLEP had a greater uroflowmetry improvement compared to open adenomectomy and TURP,” the investigators concluded. “The mean hospital stay and postoperative catheterization days were reduced compared to open adenomectomy, but there were no differences in this aspect with TURP.”
Novel oncolytic immunotherapy plus pembrolizumab active in BCG-unresponsive NMIBC
April 13th 2022Early findings from the phase 2 CORE1 trial showed that the combination of the novel oncolytic immunotherapy CG0070 and the immune checkpoint inhibitor pembrolizumab was safe and active in patients with BGG-unresponsive NMIBC.
Genetically-adjusted PSA may address overdiagnosis/overtreatment issues of prostate cancer screening
April 11th 2022Results shared during the 2022 AACR Annual Meeting suggested that genetic adjustment of prostate-specific antigen may reduce overdiagnosis of prostate cancer, de-escalate invasive testing, and improve the detection of aggressive disease.
Longer follow-up shows improved DFS with nivolumab in high-risk muscle-invasive urothelial carcinoma
December 1st 2021According to extended follow-up from the phase 3 Checkmate 274 trial, nivolumab continued to demonstrate improved disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma.
Around the Practice: Expert Offers Update in Genitourinary Cancer Cases
May 18th 2021Looking back at the November 2020 installment of Urology Times’ Around the Practice, a virtual, monthly live case event focused on genitourinary cancers, Raoul S. Concepcion, MD, FACS, offers an update on clinical implications from two prostate cancer cases.
Next-generation imaging marks dawn of new era in prostate cancer paradigm
March 16th 2021At the New York GU 14th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Phillip J. Koo, MD, highlighted the potential of next-generation imaging to revolutionize the management of patients with prostate cancer.
18F-DCFPyL may aid in staging men with metastatic, nonmetastatic relapsed prostate cancer
February 12th 2021The novel PSMA-targeted radiopharmaceutical for PET identified M1 disease in the majority of patients examined who otherwise had locoregional disease, according to a subanalysis of the OSPREY trial.
Exceeding exercise guidelines may reduce likelihood of low T in men
May 27th 2020Men whose activity exceeded guideline-based exercise levels experienced a decreased likelihood of lower serum testosterone, according to study results presented at the American Urological Association 2020 Virtual Experience.